ORIFARM GENERICS HOLDING A/S: Financial statements 2015
CVR: 27347223
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
ORIFARM GENERICS HOLDING A/S (CVR 27347223) has filed annual accounts for 2015. In 2015, the company reported a gross profit of DKK 5,654,000 and a net result of DKK 5,160,000 compared with DKK 4,116,000 the year before. That is a decrease of 31.3% compared with the year before. Equity in the 2015 report amounted to DKK 194,332,000. The solvency ratio was 39.5%.
- Gross Profit
- DKK 5,654,000
- Profit/Loss
- DKK 5,160,000
- Equity
- DKK 194,332,000
- Total Assets
- DKK 492,026,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 5.7M | 5.2M | 194.3M | - |
| 2014 | - | 8.2M | 4.1M | 15.3M | - |
| 2013 | - | 6.8M | -150K | 11.5M | - |
| 2012 | - | 13.1M | 7.1M | 12M | - |
Official annual report
How creditworthy is ORIFARM GENERICS HOLDING A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of August 26, 2015, Claus Christian Bayer has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
As of August 26, 2015, Rolf Eckersberg has joined the board of directors of ORIFARM GENERICS HOLDING A/S.
ORIFARM GENERICS HOLDING A/S has published its annual report for 2014. Gross profit came to DKK 8,233,000, and the net result was DKK 4,116,000.
About ORIFARM GENERICS HOLDING A/S
ORIFARM GENERICS HOLDING A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2003. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named COPYFARM HOLDING A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GROUP A/S. The company has 0 employees (2016). In 2025, the company reported revenue of DKK 459,463,000 and a net result of DKK 273,125,000 compared with DKK 89,363,000 the year before. Equity in the 2025 report amounted to DKK 2,399,752,000.
